Figure 6
Figure 6. Spleen size of moribund mice reconstituted with Tet-o-MYC/MIT-NOTCHIC bone marrow does not significantly reduce after Dox treatment. (A) Area (length × width) of moribund mice reconstituted with Tet-o-MYC/MIT-NOTCHIC bone marrow, untreated with Dox (No Dox) or treated for 2 weeks with Dox. N.S. indicates not significant. P = .8257 (Student t test). n = 6. (B) Quantification of CD4+CD8− and CD4+CD8+ T cells in spleens of mice with Tet-o-MYC/MIT-NOTCHIC tumors untreated or treated with Dox for 2 weeks. There was no significant change (N.S.) in the size of spleens of mice with Tet-o-MYC/MIT-NOTCHIC treated with Dox (P = .8574; Student t test). n = 6.

Spleen size of moribund mice reconstituted with Tet-o-MYC/MIT-NOTCHIC bone marrow does not significantly reduce after Dox treatment. (A) Area (length × width) of moribund mice reconstituted with Tet-o-MYC/MIT-NOTCHIC bone marrow, untreated with Dox (No Dox) or treated for 2 weeks with Dox. N.S. indicates not significant. P = .8257 (Student t test). n = 6. (B) Quantification of CD4+CD8 and CD4+CD8+ T cells in spleens of mice with Tet-o-MYC/MIT-NOTCHIC tumors untreated or treated with Dox for 2 weeks. There was no significant change (N.S.) in the size of spleens of mice with Tet-o-MYC/MIT-NOTCHIC treated with Dox (P = .8574; Student t test). n = 6.

Close Modal

or Create an Account

Close Modal
Close Modal